Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Mar

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs

Cumulative Incidence of Advanced Breast Cancer in Japanese Women Aged 40 to 49 Years With Addition of Ultrasonography to Mammography Screening

HPV Vaccination Protection From Cervical Cancer Sustained Long Term

Five-Year Outcomes With First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma